United States· US:73536-511_801f0478-b00c-4e98-90c0-0a32201be6a2
BESREMi Pen
A ropeginterferon alfa-2b product containing ropeginterferon alfa-2b, registered in United States by PharmaEssentia USA. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ropeginterferon alfa-2b is registered in 12 of 19 countries.
Countries holding a registration under ATC L03AB15 (ropeginterferon alfa-2b), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Ropeginterferon alfa-2b · ATC L03AB15
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ROPEGINTERFERON ALFA-2B
- Manufacturer
- PharmaEssentia USA
- Country
- United States (US)
- ATC code
- L03AB15
- ATC class
- Ropeginterferon alfa-2b
- Defined daily dose
- 18 mcg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1173536-511-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ropeginterferon alfa-2b in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandBesremi 500 microgram/0.5 ml Solution for injection in pre-filled penAop Orphan Pharmaceuticals GmbH
- NetherlandsBesremi 500 microgram/0,5 ml oplossing voor injectie in een voorgevulde penAOP Orphan Pharmaceuticals AG
- FinlandBesremiOrifarm Oy
- NorwayBesremiOrifarm AS
- CzechiaBESREMIAOP Orphan Pharmaceuticals GmbH, Wien
- SwitzerlandBesremi
- BelgiumBesremi 250 µg/0.5 mlAOP Orphan Pharmaceuticals
- IcelandBesremiAOP Orphan Pharmaceuticals GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Besremi
- Liechtenstein · Besremi
- Norway · Besremi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/932682ca-aa7b-454d-9605-588583bdede1 GET /v1/drugs/932682ca-aa7b-454d-9605-588583bdede1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "500",
"substance": "ROPEGINTERFERON ALFA-2B",
"productndc": "73536-511",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "ug/.5mL",
"application_number": "BLA761166",
"marketing_category": "BLA"
}See everything about ropeginterferon alfa-2b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.